Login to Your Account

Valeant wins FDA approval for Siliq

By Michael Fitzhugh
Staff Writer

Thursday, February 16, 2017

Valeant Pharmaceuticals International Inc. won a widely anticipated FDA approval for its moderate to severe plaque psoriasis drug, Siliq (brodalumab), complete with an expected black box warning for suicidal ideation and behavior that analysts expect could hamper sales.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription